Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Role of CXCL13 and CXCL9 in Early Breast Cancer.
Razis E, Kalogeras KT, Kotsantis I, Koliou GA, Manousou K, Wirtz R, Veltrup E, Patsea H, Poulakaki N, Dionysopoulos D, Pervana S, Gogas H, Koutras A, Pentheroudakis G, Christodoulou C, Linardou H, Pavlakis K, Koletsa T, Pectasides D, Zagouri F, Fountzilas G. Razis E, et al. Clin Breast Cancer. 2020 Feb;20(1):e36-e53. doi: 10.1016/j.clbc.2019.08.008. Epub 2019 Sep 5. Clin Breast Cancer. 2020. PMID: 31699671
Technology evaluation: TriGem, Titan.
Razis E, Fountzilas G. Razis E, et al. Curr Opin Mol Ther. 2003 Apr;5(2):204-7. Curr Opin Mol Ther. 2003. PMID: 12772513 Review.
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D. Fountzilas G, et al. Among authors: razis e. Clin Breast Cancer. 2003 Jun;4(2):120-5. doi: 10.3816/cbc.2003.n.017. Clin Breast Cancer. 2003. PMID: 12864940
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Fountzilas G, Christodoulou C, Tsavdaridis D, Kalogera-Fountzila A, Aravantinos G, Razis E, Kalofonos HP, Papakostas P, Karina M, Gogas H, Skarlos D. Fountzilas G, et al. Among authors: razis e. Cancer Invest. 2004;22(5):655-62. doi: 10.1081/cnv-200032980. Cancer Invest. 2004. PMID: 15581045 Clinical Trial.
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G, Pectasides D, Kalogera-Fountzila A, Skarlos D, Kalofonos HP, Papadimitriou C, Bafaloukos D, Lambropoulos S, Papadopoulos S, Kourea H, Markopoulos C, Linardou H, Mavroudis D, Briasoulis E, Pavlidis N, Razis E, Kosmidis P, Gogas H. Fountzilas G, et al. Among authors: razis e. Breast Cancer Res Treat. 2005 Jul;92(1):1-9. doi: 10.1007/s10549-005-0322-y. Breast Cancer Res Treat. 2005. PMID: 15980985 Clinical Trial.
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study.
Skarlos DV, Kalofonos HP, Fountzilas G, Dimopoulos MA, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyratzis G, Aravantinos G. Skarlos DV, et al. Among authors: razis e. Anticancer Res. 2005 Jul-Aug;25(4):3103-8. Anticancer Res. 2005. PMID: 16080573 Free article. Clinical Trial.
Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.
Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis M, Koukoulis G, Plataniotis G, Misailidou D, Bobos M, Pectasides D, Razis E, Karavelis A, Selviaridis P. Fountzilas G, et al. Among authors: razis e. Anticancer Res. 2006 Nov-Dec;26(6C):4675-86. Anticancer Res. 2006. PMID: 17214326 Free article. Clinical Trial.
105 results